Increased Intestinal Permeability Correlates with Sigmoid Mucosa alpha-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's Disease

Parkinson's disease (PD) is the second most common neurodegenerative disorder of aging. The pathological hallmark of PD is neuronal inclusions termed Lewy bodies whose main component is alpha-synuclein protein. The finding of these Lewy bodies in the intestinal enteric nerves led to the hypothesis that the intestine might be an early site of PD disease in response to an environmental toxin or pathogen. One potential mechanism for environmental toxin(s) and proinflammatory luminal products to gain access to mucosal neuronal tissue and promote oxidative stress is compromised intestinal barrier integrity. However, the role of intestinal permeability in PD has never been tested. We hypothesized that PD subjects might exhibit increased intestinal permeability to proinflammatory bacterial products in the intestine. To test our hypothesis we evaluated intestinal permeability in subjects newly diagnosed with PD and compared their values to healthy subjects. In addition, we obtained intestinal biopsies from both groups and used immunohistochemistry to assess bacterial translocation, nitrotyrosine (oxidative stress), and alpha-synuclein. We also evaluated serum markers of endotoxin exposure including LPS binding protein (LBP). Our data show that our PD subjects exhibit significantly greater intestinal permeability (gut leakiness) than controls. In addition, this intestinal hyperpermeability significantly correlated with increased intestinal mucosa staining for E. coli bacteria, nitrotyrosine, and alpha-synuclein as well as serum LBP levels in PD subjects. These data represent not only the first demonstration of abnormal intestinal permeability in PD subjects but also the first correlation of increased intestinal permeability in PD with intestinal alpha–synuclein (the hallmark of PD), as well as staining for gram negative bacteria and tissue oxidative stress. Our study may thus shed new light on PD pathogenesis as well as provide a new method for earlier diagnosis of PD and suggests potential therapeutic targets in PD subjects. Trial Registration Clinicaltrials.gov NCT01155492

[1]  M. Sofroniew,et al.  Starring roles for astroglia in barrier pathologies of gut and brain , 2007, Laboratory Investigation.

[2]  R. Mohney,et al.  Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia , 2000, The Journal of Neuroscience.

[3]  Stephen F. Carroll,et al.  Dual Role of Lipopolysaccharide (LPS)-Binding Protein in Neutralization of LPS and Enhancement of LPS-Induced Activation of Mononuclear Cells , 2001, Infection and Immunity.

[4]  M. Huber,et al.  Absence of TRIF Signaling in Lipopolysaccharide-Stimulated Murine Mast Cells , 2011, The Journal of Immunology.

[5]  P S Whitton,et al.  Inflammation as a causative factor in the aetiology of Parkinson's disease , 2007, British journal of pharmacology.

[6]  Aj Lees,et al.  Parkinson's disease (vol 373, pg 2055, 2009) , 2009 .

[7]  Hitoshi Takahashi,et al.  Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system , 2004, Acta Neuropathologica.

[8]  P. Damier,et al.  Pathological lesions in colonic biopsies during Parkinson’s disease , 2008, Gut.

[9]  S. Ito,et al.  Lipopolysaccharides enhance the action of bradykinin in enteric neurons via secretion of interleukin‐1β from enteric glial cells , 2009, Journal of neuroscience research.

[10]  A. Keshavarzian,et al.  Resolution of common dietary sugars from probe sugars for test of intestinal permeability using capillary column gas chromatography. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  A. Keshavarzian,et al.  Intestinal barrier: An interface between health and disease , 2003, Journal of gastroenterology and hepatology.

[12]  Jau-Shyong Hong,et al.  Neuroinflammation and α-Synuclein Dysfunction Potentiate Each Other, Driving Chronic Progression of Neurodegeneration in a Mouse Model of Parkinson’s Disease , 2011, Environmental health perspectives.

[13]  M. Pop,et al.  Metagenomic Analysis of the Human Distal Gut Microbiome , 2006, Science.

[14]  H. Braak,et al.  Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.

[15]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[16]  R. Knight,et al.  The Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice , 2009, Science Translational Medicine.

[17]  M. McGrath,et al.  Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS) , 2009, Journal of Neuroimmunology.

[18]  P. Damier,et al.  Colonic Biopsies to Assess the Neuropathology of Parkinson's Disease and Its Relationship with Symptoms , 2010, PloS one.

[19]  R. Shulman,et al.  Effects of Timing, Sex, and Age on Site-specific Gastrointestinal Permeability Testing in Children and Adults , 2010, Journal of pediatric gastroenterology and nutrition.

[20]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[21]  C. Tanner,et al.  Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 , 2007, Neurology.

[22]  T. Powley,et al.  Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: Autonomic pathway implicated in Parkinson's disease? , 2008, Neuroscience.

[23]  P. Mcgeer,et al.  Inflammation and the Degenerative Diseases of Aging , 2004, Annals of the New York Academy of Sciences.

[24]  P. Thompson,et al.  Modulatory effects of sCD14 and LBP on LPS-host cell interactions , 2005, Journal of endotoxin research.

[25]  N. Cerf-Bensussan,et al.  Multiple facets of intestinal permeability and epithelial handling of dietary antigens , 2010, Mucosal Immunology.

[26]  F. Barale,et al.  Low-grade endotoxemia in patients with severe autism , 2010, Neuroscience Letters.

[27]  K. Shannon,et al.  Alpha‐synuclein in colonic submucosa in early untreated Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[28]  Mihai Pop,et al.  Microbiome Metagenomic Analysis of the Human Distal Gut , 2009 .

[29]  H. Braak,et al.  Parkinson's disease: a dual‐hit hypothesis , 2007, Neuropathology and applied neurobiology.

[30]  P. Carvey,et al.  Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide , 2009, Brain Research.

[31]  J. Schulzke,et al.  Epithelial barriers in intestinal inflammation. , 2011, Antioxidants & redox signaling.

[32]  Masamichi Yokokura,et al.  Neuroinflammation in the living brain of Parkinson's disease. , 2009, Parkinsonism & related disorders.

[33]  C. Shults.  Lewy bodies. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Srinivasan,et al.  Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease , 2009, Experimental Neurology.

[35]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[36]  G. Su,et al.  LPS-binding protein mediates LPS-induced liver injury and mortality in the setting of biliary obstruction. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[37]  K. Wakabayashi,et al.  Neuropathology of autonomic nervous system in Parkinson's disease. , 1997, European neurology.

[38]  C. Duyckaerts,et al.  The second brain and Parkinson’s disease , 2009, The European journal of neuroscience.

[39]  Hitoshi Takahashi,et al.  Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses , 2004, Acta Neuropathologica.

[40]  P. Hobson,et al.  The estimated life expectancy in a community cohort of Parkinson's disease patients with and without dementia, compared with the UK population , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[41]  F. Crews,et al.  Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration , 2007, Glia.

[42]  M. Maes,et al.  The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. , 2008, Neuro endocrinology letters.

[43]  E. Harkness,et al.  Endotoxin : is it an environmental factor in the cause of Parkinson ’ s disease ? , 2022 .

[44]  J. Gegner,et al.  Lipopolysaccharide Binding Protein-mediated Complexation of Lipopolysaccharide with Soluble CD14 (*) , 1995, The Journal of Biological Chemistry.

[45]  L. Cote,et al.  Parkinson's disease and megacolon , 1987, Neurology.

[46]  F. D'armiento,et al.  Increased mucosal nitric oxide production in ulcerative colitis is mediated in part by the enteroglial‐derived S100B protein , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[47]  D. King,et al.  Intestinal permeability and orocaecal transit time in elderly patients with Parkinson's disease. , 1996, Postgraduate medical journal.

[48]  S. Pittaluga,et al.  Damaged Intestinal Epithelial Integrity Linked to Microbial Translocation in Pathogenic Simian Immunodeficiency Virus Infections , 2010, PLoS pathogens.

[49]  H. Braak,et al.  Invited Article: Nervous system pathology in sporadic Parkinson disease , 2008, Neurology.